Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

IMMUNOTHERAPY

MSI-H: a truly agnostic biomarker?

Nature Reviews Clinical Oncology volume 17, page 68 (2020)Cite this article

Subjects

Access through your institution
Buy or subscribe

The FDA accelerated approvals of pembrolizumab for patients with microsatellite instability-high (MSI-H)/deficient DNA mismatch repair (dMMR) metastatic or unresectable solid tumours, and of nivolumab (with or without ipilimumab), for patients with MSI-H/dMMR metastatic colorectal cancer (CRC) provide potentially curative options for such patients. Now, data from KEYNOTE-164 and KEYNOTE-158 provide further evidence on the efficacy of pembrolizumb in this setting.

At a median follow-up duration of 31.3 months (group A) and 24.2 months (group B), both groups had an ORR of 33%. Median overall survival (OS) durations were 31.4 months in group A and not reached in group B (2-year OS 63%), with similar risks of grade 3–4 treatment-related adverse events (TRAEs, 16% and 13%, respectively).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original articles

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Peter Sidaway

Authors
  1. Peter Sidaway
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. MSI-H: a truly agnostic biomarker?. Nat Rev Clin Oncol 17, 68 (2020). https://doi.org/10.1038/s41571-019-0310-5

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-019-0310-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing